[저자] Ralph C Wang, Michael Gottlieb, Juan Carlos C Montoy, Robert M Rodriguez, Huihui Yu, Erica S Spatz, Christopher W Chandler, Joann G Elmore, Paavali A Hannikainen, Anna Marie Chang, Mandy Hill, Ryan M Huebinger, Ahamed H Idris, Katherine Koo, Shu-Xia Li, Samuel McDonald, Graham Nichol, Kelli N O’Laughlin, Ian D Plumb, Michelle Santangelo, Sharon Saydah, Kari A Stephens, Arjun K Venkatesh, Robert A Weinstein,
Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
WeinsteinRobert AMDGottliebMichaelMDSantangeloMichelleMSKooKatherineMS-HSMDerdenAntoniaBAGottliebMichaelMDGatlingKristynMSGuzmanDiegoYangGeoffreyBSKaadanMarshallBSHassaballaMinnaBSJergerRyanAhmedZohaibBSChoiMichaelBSVenkateshArjunMD, MBA, MHSSpatzEricaMD, MHSLinZhenqiuPhDLiShu-XiaPhDYuHuihuiPhDLiuMengniMSVenkateshArjunMD, MBA, MHSSpatzEricaMD, MPHUlrichAndrewMDKinsmanJeremiahMPH, NREMTDorneyJocelynMPHPierceSenytePuenteXavierNicholGrahamMDStephensKariPhD, MSAndersonJillBSN, RNMorseDanaRN, BSNAdamsKarenBAMaatZenouraStoberTracyBA, MAO’LaughlinKelli NMD, MPHGentileNikkiMD, PhDGeyerRachel EMPHWillisMichaelAS, BSHSRuizLuisBAMaloneKerryBAParkJasmineRisingKristinMD, MSKeanEfratMDKellyMorganBSSchaefferKevinHannikainenPaavaliBSShughartLindseyBSShughartHaileyBA, CCRPRenziNicoleRNAmadioGraceGrauDylanWattsPhillipBA, MM, CCRPChengDavidBSMiaoJessicaBAShuttyCarlyBSNCharltonAlexHillMandyDrPH, MPHSiteRyan HuebingerMDChavezSummerDO, MPH, MPMKaneArunBANikonowiczPeterIdrisAhamed HMDMcDonaldSamuelMDGallegosDavidMartinRileyElmoreJoannMD, MPHWiskLaurenPhDL’HommedieuMichellePhDChandlerChrisBAEguchiMeganMPHRoldanKate DiazMPHVillegasNicoleBSMorenoRaulBARodriguezRobertMDWangRalph CMD, MASMontoyJuan CarlosMD, PhDKemballRobinMPHChanVirginiaBSChavezCecilia LaraWongAngelaBAArreguinMireyaPlumbIan DMBBS, MScHallAron JDVM, MSPHSaydahSharonPhDBriggs-HagenMelissaMD, MPH
, Robert A Weinstein, Michael Gottlieb, Michelle Santangelo, Katherine Koo, Antonia Derden, Michael Gottlieb, Kristyn Gatling, Diego Guzman, Geoffrey Yang, Marshall Kaadan, Minna Hassaballa, Ryan Jerger, Zohaib Ahmed, Michael Choi, Arjun Venkatesh, Erica Spatz, Zhenqiu Lin, Shu-Xia Li, Huihui Yu, Mengni Liu, Arjun Venkatesh, Erica Spatz, Andrew Ulrich, Jeremiah Kinsman, Jocelyn Dorney, Senyte Pierce, Xavier Puente, Graham Nichol, Kari Stephens, Jill Anderson, Dana Morse, Karen Adams, Zenoura Maat, Tracy Stober, Kelli N O’Laughlin, Nikki Gentile, Rachel E Geyer, Michael Willis, Luis Ruiz, Kerry Malone, Jasmine Park, Kristin Rising, Efrat Kean, Morgan Kelly, Kevin Schaeffer, Paavali Hannikainen, Lindsey Shughart, Hailey Shughart, Nicole Renzi, Grace Amadio, Dylan Grau, Phillip Watts, David Cheng, Jessica Miao, Carly Shutty, Alex Charlton, Mandy Hill, Ryan Huebinger Site, Summer Chavez, Arun Kane, Peter Nikonowicz, Ahamed H Idris, Samuel McDonald, David Gallegos, Riley Martin, Joann Elmore, Lauren Wisk, Michelle L’Hommedieu, Chris Chandler, Megan Eguchi, Kate Diaz Roldan, Nicole Villegas, Raul Moreno, Robert Rodriguez, Ralph C Wang, Juan Carlos Montoy, Robin Kemball, Virginia Chan, Cecilia Lara Chavez, Angela Wong, Mireya Arreguin, Ian D Plumb, Aron J Hall, Sharon Saydah, Melissa Briggs-Hagen
[Category] update2024,
[Article Type] Major Article
[Source] PMC
Abstract Background While prior work examining severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern focused on hospitalization and death, less is known about differences in clinical presentation. We compared the prevalence of acute symptoms across pre-Delta, Delta, and Omicron. Methods We conducted an analysis of the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE), a cohort study enrolling symptomatic SARS-CoV-2-positive participants. We determined the association between the pre-Delta, Delta, and Omicron time periods and the prevalence of 21 coronavirus disease 2019 (COVID-19) acute symptoms. Results We enrolled 4113 participants from December 2020 to June 2022. Pre-Delta vs Delta vs Omicron participants had increasing sore throat (40.9%, 54.6%, 70.6%; P < .001), cough (50.9%, 63.3%, 66.7%; P < .001), and runny noses (48.9%, 71.3%, 72.9%; P < .001). We observed reductions during Omicron in chest pain (31.1%, 24.2%, 20.9%; P < .001), shortness of breath (42.7%, 29.5%, 27.5%; P < .001), loss of taste (47.1%, 61.8%, 19.2%; P < .001), and loss of smell (47.5%, 55.6%, 20.0%; P < .001). After adjustment, those infected during Omicron had significantly higher odds of sore throat vs pre-Delta (odds ratio [OR], 2.76; 95% CI, 2.26–3.35) and Delta (OR, 1.96; 95% CI, 1.69–2.28). Conclusions Participants infected during Omicron were more likely to report symptoms of common respiratory viruses, such as sore throat, and less likely to report loss of smell and taste. Trial registration NCT04610515.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, variants of concern, COVID-19 symptoms,